Core Insights - The report indicates a shift from profit to loss in self-breeding pig farming, driven by ongoing capacity regulation policies [1][7][33] - The overall investment rating for the agricultural sector remains optimistic [1] Group 1: Swine Farming Data Tracking - The number of breeding sows decreased by 0.80% in August compared to July, indicating a slight contraction in supply [19] - The price of market pigs has declined, with the average selling price on September 18 being 13.15 CNY/kg, a week-on-week decrease of 2.74% [28][29] - Profitability in self-breeding and purchased pig farming has turned negative, with losses of 24.44 CNY/head and 199.31 CNY/head respectively as of September 19 [33][36] Group 2: Poultry Farming Data Tracking - The average price of white feather broilers on September 19 was 6.88 CNY/kg, reflecting a week-on-week decrease of 1.99% [34][37] - The profit from white feather broiler farming was negative at -1.56 CNY/bird [34][37] Group 3: Animal Health Data Tracking - The demand for animal health products is expected to rebound, with significant growth in vaccine approvals and product launches [43] - The industry is seeing a recovery in sales, with notable increases in the issuance of various vaccines [43] Group 4: Seed Industry Data Tracking - The average prices for wheat, soybean meal, and corn as of September 19 were 2430 CNY/ton, 3032 CNY/ton, and 2360 CNY/ton respectively, with corn prices showing a year-to-date increase of 11.2% [47][49] Group 5: Pet Industry Data Tracking - Pet food exports in July amounted to 930 million CNY, a year-on-year decrease of 3.0% [52][53] - Domestic sales of pet food continue to grow, with e-commerce platforms showing an overall growth rate of 8% in August [55][57]

Core Points - The animal health sector experienced a decline of 0.36% on September 22, with Jinhe Biology leading the drop [1] - The Shanghai Composite Index closed at 3828.58, up 0.22%, while the Shenzhen Component Index closed at 13157.97, up 0.67% [1] Stock Performance Summary - The following stocks in the animal health sector showed notable performance: - Shoufeng Holdings (002141) closed at 3.94, up 3.14% with a trading volume of 307,400 shares and a turnover of 118 million yuan [1] - ST Lvkang (002868) closed at 28.23, up 2.43% with a trading volume of 24,900 shares and a turnover of 69.04 million yuan [1] - Shengbiotech (600201) closed at 9.11, up 1.22% with a trading volume of 396,800 shares and a turnover of 364 million yuan [1] - Jinhe Biology (002688) closed at 6.74, down 2.18% with a trading volume of 234,800 shares and a turnover of 158 million yuan [2] - Other stocks such as Haili Biology (603718) and Zhongmu Co. (600195) also experienced declines of 1.43% and 1.39% respectively [1][2] Capital Flow Analysis - On that day, the animal health sector saw a net outflow of 53.34 million yuan from institutional investors, while retail investors contributed a net inflow of 67.06 million yuan [2]

Core Viewpoint - The stock price of Reap Bio fell by 2.00% on September 22, 2023, with a current price of 21.51 CNY per share and a market capitalization of 9.997 billion CNY [1] Group 1: Stock Performance - Reap Bio's stock has increased by 18.99% year-to-date, but has decreased by 2.14% in the last five trading days and 8.39% over the last 20 days [2] - The stock has shown a 10.76% increase over the past 60 days [2] Group 2: Company Overview - Reap Bio, established on August 2, 2001, and listed on September 17, 2010, is located in the Tianjin Free Trade Zone and specializes in veterinary biological products, chemical drugs, biological agents, and animal health products [2] - The company's main business revenue composition is 77.95% from animal health and 22.05% from the pet supply chain [2] - Reap Bio is classified under the agricultural and animal health industry, with concepts including avian influenza drugs, pet economy, raw materials, synthetic biology, and investments in the New Third Board [2] Group 3: Financial Performance - For the first half of 2025, Reap Bio achieved a revenue of 1.708 billion CNY, representing a year-on-year growth of 55.37%, and a net profit attributable to the parent company of 257 million CNY, up 61.19% year-on-year [2] - Since its A-share listing, Reap Bio has distributed a total of 1.371 billion CNY in dividends, with 462 million CNY distributed over the last three years [3] Group 4: Shareholder Information - As of June 30, 2025, Reap Bio had 26,000 shareholders, with an average of 12,883 circulating shares per person [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited and Guotai CSI Livestock Breeding ETF, with notable changes in their holdings [3]

Market Overview - On September 19, the animal health sector declined by 0.26% compared to the previous trading day, with the driving force leading the decline [1] - The Shanghai Composite Index closed at 3820.09, down 0.3%, while the Shenzhen Component Index closed at 13070.86, down 0.04% [1] Stock Performance - Notable stock movements included: - *ST Lvkang (002868): Closed at 27.56, up 4.99% with a trading volume of 38,500 shares and a turnover of 105 million yuan [1] - Kexin Biological (688526): Closed at 18.08, up 0.39% with a trading volume of 22,700 shares and a turnover of 40.94 million yuan [1] - Driving Force (838275): Closed at 10.50, down 4.11% with a trading volume of 21,200 shares and a turnover of 22.63 million yuan [2] Capital Flow - The animal health sector experienced a net outflow of 91.4 million yuan from institutional investors, while retail investors saw a net inflow of 70.15 million yuan [2] - The capital flow for individual stocks showed: - RuiPu Biological (300119): Net inflow of 16.56 million yuan from institutional investors, but a net outflow of 21.57 million yuan from retail investors [3] - *ST Lvkang (002868): Net inflow of 6.13 million yuan from institutional investors, with a net outflow of 4.21 million yuan from retail investors [3]

Market Overview - On September 18, the animal health sector declined by 0.77% compared to the previous trading day, with Huisheng Biological leading the decline [1] - The Shanghai Composite Index closed at 3831.66, down 1.15%, while the Shenzhen Component Index closed at 13075.66, down 1.06% [1] Stock Performance - The following stocks in the animal health sector showed notable performance: - *ST Lvkang (002868): Closed at 26.25, up 5.00% with a trading volume of 3433 lots [1] - Shengbi Biological (600201): Closed at 66.8, down 2.39% with a trading volume of 55.74 million [1] - Ruipu Biological (300119): Closed at 22.06, unchanged with a trading volume of 111.3 million [1] - Other stocks such as Jinhai Biological (002688) and Shunlian Biological (688098) also experienced declines of 1.98% and 2.02% respectively [1][2] Capital Flow - The animal health sector experienced a net outflow of 126 million yuan from institutional investors, while retail investors saw a net inflow of 92.38 million yuan [2] - The following stocks had significant capital flow: - Ruipu Biological: Net inflow of 12.35 million yuan from institutional investors [3] - *ST Lvkang: Net outflow of 3.83 million yuan from institutional investors [3] - Jinhai Biological: Net outflow of 25.51 million yuan from institutional investors [3]

Core Viewpoint - Reap Bio (300119.SZ) has recently obtained a new veterinary drug registration certificate from the Ministry of Agriculture and Rural Affairs, indicating progress in its product development and regulatory approval process [1]. Group 1: New Drug Registration - Reap Bio's subsidiary, South China Agricultural University Biological Pharmaceutical Co., Ltd. (referred to as "South China Bio"), has successfully registered two diagnostic reagent products as veterinary drugs [1]. - The company has also received approval for two vaccine products after passing the production strain change review by the Ministry of Agriculture and Rural Affairs [1]. Group 2: Details of New Veterinary Drugs - The newly registered veterinary drugs include: - Recombinant Cat Interferon ω (lyophilized form) developed by Reap Bio and Zhongke Baike (Tianjin) Biopharmaceutical Co., Ltd., classified as a Class II veterinary drug [2]. - Avian Influenza Virus H7 subtype (rLN79 strain) and H5 subtype (rFJ56 strain) diagnostic reagents developed in collaboration with South China Agricultural University and other partners [2]. - The vaccine products include: - Bivalent inactivated vaccine for Avian Influenza Virus (H5 subtype) combining strains H5N6 rHN503 and H5N1 rHN504, developed by multiple institutions including South China Agricultural University [2]. - Quadrivalent inactivated vaccine for Avian Influenza Virus (H5 and H7 subtypes) combining multiple strains, also developed by South China Agricultural University and its partners [2].

Core Viewpoint - Reap Bio (300119.SZ) has recently obtained a new veterinary drug registration certificate from the Ministry of Agriculture and Rural Affairs, indicating progress in its product development and regulatory approval process [1]. Group 1: New Drug Registration - Reap Bio's subsidiary, South China Agricultural University Biological Pharmaceutical Co., Ltd. (referred to as "South China Bio"), has successfully registered two diagnostic reagent products as veterinary drug products [1]. - The company has also received approval for two vaccine products, which have passed the production strain change review by the Ministry of Agriculture and Rural Affairs [1]. Group 2: Details of New Veterinary Drugs - The newly registered veterinary drugs include: - Recombinant Cat Interferon ω (lyophilized type) developed by Reap Bio and Zhongke Baike (Tianjin) Biological Pharmaceutical Co., Ltd. [2] - Avian Influenza Virus H7 subtype (rLN79 strain) developed by South China Agricultural University and other partners [2]. - Additionally, two inactivated vaccines for avian influenza have been applied for, including: - Bivalent inactivated vaccine for Avian Influenza Virus (H5N6 rHN503 strain + H5N1 rHN504 strain) [2]. - Quadrivalent inactivated vaccine for Avian Influenza Virus (H5N6 rHN503 strain + H5N1 rHN504 strain, H7N9 rHN705 strain + rHN706 strain) [2].

证券代码：300119 证券简称：瑞普生物 公告编号：2025-073 瑞普生物股份有限公司 关于五种兽药产品获农业农村部批准的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 根据《兽药管理条例》和《兽药注册办法》的规定，瑞普生物股份有限公司 （以下简称"公司"）近日获得由农业农村部核发的《新兽药注册证书》，子公 司广州市华南农大生物药品有限公司（以下简称"华南生物"）研发的 2 款诊断 试剂产品获批兽药产品注册，2 款疫苗产品通过农业农村部生产毒种变更备案审 查。 详情如下： 本产品为 H7N9 亚型高致病性禽流感病毒疫苗的专用诊断试剂，是开展 H7N9 亚型禽流感疫苗免疫效果评估、疫情监测、流行病学调查及进出口检疫的 必备工具，对禽流感的有效防控、保障养禽业健康发展和公共卫生安全具有重大 意义。 （一）兽药注册情况 | 新兽药名称 | | 研制单位 | 类别 | 新兽药注册证书号 | | --- | --- | --- | --- | --- | | 重组猫干扰素ω（冻干型） | | 瑞普生物股份有限公司、中科拜 | 二类 | （2025）新兽药证字 ...

Market Overview - On September 16, the animal health sector declined by 0.41%, with *ST Lvkang leading the drop [1] - The Shanghai Composite Index closed at 3861.87, up 0.04%, while the Shenzhen Component Index closed at 13063.97, up 0.45% [1] Stock Performance - Key stocks in the animal health sector showed mixed performance, with the following notable movements: - Xianfeng Holdings (002141) increased by 2.27% to close at 4.06 [1] - Haili Biological (603718) rose by 1.27% to 7.17 [1] - *ST Lvkang (002868) fell by 4.34% to 23.81, leading the decline [2] - The trading volume and turnover for selected stocks were significant, with Xianfeng Holdings achieving a turnover of 1.02 billion [1] Capital Flow Analysis - The animal health sector experienced a net outflow of 15.97 million from institutional investors, while retail investors saw a net inflow of 11.29 million [2][3] - Notable capital flows included: - Biological Shares (600201) had a net inflow of 12.28 million from institutional investors [3] - *ST Lvkang (002868) saw a net outflow of 2.89 million from institutional investors [3] - Retail investors contributed positively to several stocks, including a net inflow of 12.59 million into Shenyuan Biological (688098) [3]

Core Insights - The animal health sector experienced a 1.14% increase on September 15, with BioShares leading the gains [1] - The Shanghai Composite Index closed at 3860.5, down 0.26%, while the Shenzhen Component Index closed at 13005.77, up 0.63% [1] Stock Performance - BioShares (600201) closed at 8.82, up 7.17% with a trading volume of 624,100 shares and a turnover of 539 million yuan [1] - Dayu Biological (871970) closed at 11.50, up 6.09% with a trading volume of 124,300 shares and a turnover of 139 million yuan [1] - Other notable performers include: - Jinhai Biological (002688) at 7.20, up 3.00% [1] - Ruipu Biological (300119) at 21.98, up 1.76% [1] - Zhongmu Co. (600195) at 7.50, up 1.63% [1] Capital Flow - The animal health sector saw a net outflow of 25.577 million yuan from institutional investors, while retail investors contributed a net inflow of 6.5625 million yuan [2] - The capital flow for individual stocks indicates: - Jinhai Biological had a net inflow of 32.1651 million yuan from institutional investors [3] - Zhongmu Co. had a net inflow of 6.8986 million yuan from institutional investors [3] - Ruipu Biological experienced a net outflow of 1.1475 million yuan from institutional investors [3]